carbamazepine oxcarbazepine — Competitive Intelligence Brief

carbamazepine oxcarbazepine (carbamazepine oxcarbazepine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels Neurology Small molecule

Target snapshot

carbamazepine oxcarbazepine (carbamazepine oxcarbazepine) — Odense University Hospital. Oxcarbazepine blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizure propagation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
carbamazepine oxcarbazepine TARGET	carbamazepine oxcarbazepine	Odense University Hospital	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Perineural Dexamethasone and bupivacaine	Perineural Dexamethasone and bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Local anesthetic with adjuvant corticosteroid	Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
Levobupivacaine wound infiltration	Levobupivacaine wound infiltration	University of Genova	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Lidocaine-chlorprocaine combination	Lidocaine-chlorprocaine combination	Hadassah Medical Organization	marketed	Local anesthetic combination	Voltage-gated sodium channels
Lidocaine HCl 1%	Lidocaine HCl 1%	HaEmek Medical Center, Israel	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine injection flushed	Lidocaine injection flushed	Wake Forest University Health Sciences	marketed	Local anesthetic	Voltage-gated sodium channels
Ropivacaine/Fentanyl	Ropivacaine/Fentanyl	National Institute for Tuberculosis and Lung Diseases, Poland	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

1. University of Sao Paulo · 2 drugs in this class
2. Mario Negri Institute for Pharmacological Research · 2 drugs in this class
3. Janssen Korea, Ltd., Korea · 1 drug in this class
4. Johnson & Johnson Taiwan Ltd · 1 drug in this class
5. Ministry of Health and Sports, Myanmar · 1 drug in this class
6. Odense University Hospital · 1 drug in this class
7. UCB BIOSCIENCES GmbH · 1 drug in this class
8. University Hospitals Cleveland Medical Center · 1 drug in this class
9. Eisai Korea Inc. · 1 drug in this class
10. Upsher-Smith Laboratories · 1 drug in this class